Fulcrum Therapeutics (FULC) and Slate Medicines agreed to combine in an all-stock transaction, creating a company focused on developing next-generation migraine therapies.
FULC shares jumped nearly +10% premarket
Under the deal, existing Fulcrum shareholders are expected to own 5% of the To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser